Pfizer Ventures, the venture investment group for Pfizer, is investing $600 million in biotechnology, with 25% dedicated to neuroscience. The company initially will focus on neurodegeneration, neuroinflammation and neurometabolic disorders.
Sign up for AIChE SmartBrief
News for chemical engineers
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.